Articles tagged "Immunosuppression"

2015 American Transplant Congress
NFAT Regulated Cytokine Gene Expression for Immune Monitoring in Kidney Transplant Recipients
V. Tatapudi, A. Webber, C. Leung, F. Vincenti.
Div. of Nephrology, Dept. of Medicine, University of California, San Francisco Medical Center, San Francisco, CA.
Purpose of Study:To demonstrate that profiling kidney transplant recipients (KTR) on Tacrolimus (Tac) based immunosuppression based on quantitative analysis of NFAT (nuclear factor of activated…
2015 American Transplant Congress
Long-Term Follow-Up After Conversion from Twice-Daily Tacrolimus Formulation to Once-Daily Tacrolimus Formulation in Pediatric Kidney Transplantation
C. Choi, A. Han, S. Min, S.-K. Min, T. Lee, I.-M. Jung, S. Kim, J. Ha.
Surgery, Seoul National University College of Medicine, Seoul, Republic of Korea.
PurposeTacrolimus is one of the most frequently used immunosuppressants in pediatric kidney transplantation (KT) as in adult. In Pediatric kidney recipients, it is more important…
2015 American Transplant Congress
Induction With ATG Is Not Associated With Increased Infections After Kidney Transplant Among HIV Positive Patients: Results of a National Study
L. Kucirka,¹ C. Durand,¹ S. Bae,¹ J. Locke,² D. Segev.¹
¹JHU, Baltimore; ²UAB, Birmingham.
Anti-thymocyte globulin (ATG) is widely used for induction, particularly for those at high risk for rejection. HIV+ kidney transplant (KT) recipients have 3 fold higher…
2015 American Transplant Congress
Effectiveness of Protocol-Driven Induction Therapy in Adult Kidney Transplant Recipients
J. Casale, J. Fleming, D. Taber, C. Staino, K. Boyle, K. Covert, N. Pilch, H. Meadows, C. Mardis, K. Chavin, C. Bratton, J. McGillicuddy, T. Srinivas, P. Baliga.
MUSC, Charleston, SC.
Background: Induction therapy significantly improves graft outcomes in kidney transplantation, but the optimal agent based on patient characteristics and immunologic risk is unknown. While many…
2015 American Transplant Congress
Adverse Events of Maintenance Immunosuppression Following Kidney Transplantation Reported in Randomized Controlled Trials: A Systematic Review
M. Howell,^1,2 R. Yeo,² A. Tong,^1,2 J. Craig,^1,2 K. Howard,² G. Wong.^2,3
¹Centre for Kidney Research, The Children's Hospital at Westmead, Westmeand, NSW, Australia; ²School of Public Health, University of Sydney, Sydney, NSW, Australia; ³Centre for Transplant and Renal Research, Westmead Hospital, Westmead, NSW, Australia.
Aim: To evaluate the completeness of reporting of adverse events in randomized controlled trials (RCTs) of maintenance immunosuppression in kidney transplantation.Background: Side effects of maintenance…
2015 American Transplant Congress
Efficacy and Safety of Induction Therapy With Monoclonal Versus Polyclonal Antibodies in Kidney Transplant Recipients in the Last Five Years (2008-2013) in Our Institution
M. Fernández, M. López, M. Ferreira, A. Aguilar, C. Jiménez, R. Selgas.
Nephrology, La Paz Hospital, Madrid, Spain.
Induction immunosuppression in renal transplantation is not clearly defined. We analyze the efficacy and safety of the used regimens at our institution in the last…
2015 American Transplant Congress
PI3Kα and STAT1 Interplay Regulates Human Mesenchymal Stem Cell Immune Polarization
E. Kefalogianni,¹ M. Mounayar,² B. Smith,² J. Azzi,² L. Chabtini,² P. Fiorina,² M. Kraus,³ R. Briddell,⁴ W. Fodor,⁵ A. Herrlich,¹ R. Abdi.²
¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA; ²Transplantation Research Center, Brigham and Women's and Children's Hospital, Harvard Medical School, Boston, MA; ³Viacord LLC, a PerkinElmer Company, Cambridge, MA; ⁴ViaCord Processing Lab, Viacord LLC, a PerkinElmer Company, Hebron, KY; ⁵The Cell Therapy Group, Madison, CT.
The immunomodulatory capacity of mesenchymal stem cells (MSC) is critical for their use in therapeutic applications. MSC response to specific inflammatory cues allows them to…
2015 American Transplant Congress
Outcome of Renal Sparing Protocol in a Cross-Sectional Analysis After Heart Transplant
J. Kobashigawa, M. Kittleson, P. Patel, F. Liou, S. Siddiqui, D. Chang, B. Azarbal, D. Ramzy, L. Czer, J. Patel.
Cedars-Sinai Heart Institute, Los Angeles, CA.
Purpose: Calcineurin inhibitors (CNIs) are the mainstay of immunotherapy after heart transplantation. Unfortunately CNIs are associated with renal dysfunction due to nephrotoxic side effects. The…
2015 American Transplant Congress
High Within-Patient Variability in Tacrolimus Levels Is a Predictor of Late Rejection in Young Adult Kidney Transplant Recipients
J. van der Net, P. Harden.
Oxford Transplant Centre / Kidney Unit, Oxford University Hospitals NHS Trust, Oxford, United Kingdom.
Introduction: Non-adherence is an important risk factor for late rejection (rejection > 3 months post-transplant) and is the main reason why 17-29 year old kidney…
2015 American Transplant Congress
Prospective, 6 Month, Open Label, Conversion Study from Mycophenolate Mofetyl to Mycophenolic Acid Evaluating the Severity of Gastro-Intestinal Symptoms and Mycophenolic Acid Urinary Metabolite as a Surrogate Marker of Plasmatic Area Under the Curve
D. Tran,¹ A. Boucher,¹ L. Senécal,¹ V. Pichette,¹ F. Leblond,² S. Collette.¹
¹Nephrology, Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada; ²Research Center, Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada.
Introduction: Treatment with mycophenolate mofetil (MMF) often results in adverse gastro-intestinal (GI) events, which can lead to dose reductions that in turn can increase the…